Spanish pharma spend rise "acceptable":
This article was originally published in Clinica
Spain's medical technology industry will cautiously welcome news that spending on pharmaceuticals rose annually by 7.9% in 2001, to E7.2 billion ($6.36 billion), according to provisional figures released by the health ministry. The government considers this to be within "acceptable" spending levels, reports El Pais, referring to its policy of limiting pharma spending to three points above GDP growth (including inflation), after the double-figure increases of recent years. A 7.5% rise in 2000, at E6.73 billion, was preceded by average annual growth of 12.9% over the previous 13 years. High spending by the pharma sector has traditionally been seen by the medical devices sector as impacting negatively on funding available to it.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.